Phenotypic effect of GBA1 variants in individuals with and without Parkinson's disease: The RAPSODI study

Background: Variants in the GBA1 gene cause the lysosomal storage disorder Gaucher disease (GD). They are also risk factors for Parkinson's disease (PD), and modify the expression of the PD phenotype. The penetrance of GBA1 variants in PD is incomplete, and the ability to determine who among GBA1 variant carriers are at higher risk of developing PD, would represent an advantage for prognostic and trial design purposes. Objectives: To compare the motor and non-motor phenotype of GBA1 carriers and non-carriers. Methods: We present the cross-sectional results of the baseline assessment from the RAPSODI study, an online assessment tool for PD patients and GBA1 variant carriers. The assessment includes clinically validated questionnaires, a tap-test, the University of Pennsyllvania Smell Identification Test and cognitive tests. Additional, homogeneous data from the PREDICT-PD cohort were included. Results: A total of 379 participants completed all parts of the RAPSODI assessment (89 GBA1-negative controls, 169 GBA1-negative PD, 47 GBA1-positive PD, 47 non-affected GBA1 carriers, 27 GD). Eighty-six participants were recruited through PREDICT-PD (43 non-affected GBA1 carriers and 43 GBA1-negative controls). GBA1positive PD patients showed worse performance in visual cognitive tasks and olfaction compared to GBA1negative PD patients. No differences were detected between non-affected GBA1 carriers carriers and GBA1negative controls. No phenotypic differences were observed between any of the non-PD groups.Conclusions: Our results support previous evidence that GBA1-positive PD has a specific phenotype with more severe non-motor symptoms. However, we did not reproduce previous findings of more frequent prodromal PD signs in non-affected GBA1 carriers.

Automated summary

This study compared the motor and non-motor phenotypes of GBA1 carriers and non-carriers. The results showed that GBA1-positive PD patients had worse performance in visual cognitive tasks and olfaction compared to GBA1-negative PD patients. However, the study did not replicate previous findings of more frequent prodromal PD signs in non-affected GBA1 carriers.